13F Holdings
中文EN

ABVC ABVC BIOPHARMA, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1173313 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY234.3%
TTM net income YoY62.5%
TTM EPS YoY76.7%
Revenue 3-yr CAGR12.7%
Net income 3-yr CAGR—

Margins

Gross margin99.9%
Operating margin-850.7%
Net margin-773.6%
FCF margin—
EBITDA margin-840.1%

Returns

ROE-283.6%
ROA-51.4%
ROIC (approx.)-570.9%
Asset turnover0.07x

Leverage & solvency

Liabilities / assets90.4%
Debt / equity0.00x
Current ratio0.33x
Interest coverage-5.25x

Cash quality & payout

Operating cash flow / net income0.41x
Accruals ratio-30.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$296,000$509,589$152,430$969,783$355,797
Cost of revenue—$763$302,037$286,415$5,086
Gross profit—$508,826-$149,607$683,368$350,711
R&D expense$121,085$179,272$1.06M$2.69M$1.00M
SG&A expense$2.89M$2.26M$5.37M$6.07M$5.75M
Operating income-$7.15M-$4.71M-$6.77M-$15.11M-$11.71M
Interest expense$415,890$825,899$1.31M$293,968$227,210
Pretax income-$8.35M-$5.37M-$8.02M-$15.51M-$11.21M
Income tax$24,154-$110,539$256,006$797,778$825,024
Net income-$7.91M-$4.90M-$7.79M-$16.42M-$12.84M
EBITDA-$7.13M-$4.67M-$6.74M-$15.09M-$11.69M
EPS (basic)-0.39-0.42-1.80-5.19-0.51
EPS (diluted)-0.39-0.42-1.80-5.19-0.51
Weighted avg. shares (diluted)20.11M11.67M4.34M3.17M25.05M
Balance sheet
Cash & equivalents$681,480$863,815$716,780$1.39M$6.57M
Short-term investments$64,354$64,736$79,312$75,797$108,147
Receivables——$1,530$98,325$280,692
Inventory————$25,975
Current assets$3.26M$2.18M$1.66M$2.99M$7.65M
PP&E, net$12.84M$511,088$569,278$573,978$525,881
Total assets$21.82M$7.54M$7.78M$9.58M$13.70M
Current liabilities$6.92M$6.56M$6.10M$5.54M$3.69M
Short-term debt$755,512$840,252$899,250$1.89M$1.64M
Total liabilities$8.52M$6.82M$6.53M$6.34M$4.83M
Shareholders' equity$11.11M$1.23M$1.55M$3.10M$8.84M
Shares outstanding25.05M13.87M7.94M3.29M24.42M
Cash flow statement
Operating cash flow-$2.99M-$1.81M-$4.19M-$7.40M-$7.60M
Capital expenditure——$21,201$119,692$17,503
Free cash flow——-$4.21M-$7.52M-$7.62M
Investing cash flow-$1.21M—-$360,186-$1.72M-$805,966
Financing cash flow$4.64M$1.98M$3.87M$4.01M$10.00M
Depreciation & amortization$25,330$32,025$28,531$23,799$11,993
Stock-based compensation$4.14M$2.77M$536,648$7.04M$5.31M

Free plan shows the latest 5 periods; Pro shows all 19 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.